Atopic Dermatitis

At baseline and at treatment-change visits, document extent and signs with EASI when a clinician-assessed longitudinal metric is needed. EASI scores range from 0 to 72; values of 7 or less, 8 to 21, 22 to 50, and 51 to 72 correspond to mild, moderate, severe, and very severe disease, respectively. PubMedPubMedAtopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics Record a patient-reported outcome such as POEM when itch, sleep loss, or day-to-day burden is driving escalation, because EASI and POEM show only moderate correlation. PubMed+1PubMedRelationship between EASI and SCORAD severity assessments for atopic dermatitisPubMedUpdate on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection

Interpret change relative to baseline rather than relying only on an absolute EASI change. In an observational study, one-grade improvement in physician global assessment was associated with approximately 50% EASI reduction, while percent EASI responses had similar interpretation across mild, moderate, and severe baseline disease. PubMedPubMedWhat are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study A patient with limited visible eczema but high POEM may require reassessment for xerosis, sleep disruption, treatment tolerability, or an alternate contributor to symptoms rather than automatic systemic escalation. PubMed+1PubMedRelationship between EASI and SCORAD severity assessments for atopic dermatitisPubMedUpdate on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection

Before declaring topical treatment failure, verify the diagnosis and distribution. The United Kingdom diagnostic criteria can support probable atopic dermatitis; discordant anatomy or timing should prompt consideration of contact dermatitis, acute viral exanthem, or immune deficiency-associated dermatoses. PubMedPubMedUpdate on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection Chronic dermatitis present from birth is not the expected pattern for immune deficiency-associated skin disease in the cited diagnostic framework. PubMedPubMedUpdate on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection

Use topical corticosteroids as first-line anti-inflammatory therapy for flares and maintenance of mild-to-moderate atopic dermatitis. PubMedPubMedAtopic Dermatitis: A Review of Diagnosis and Treatment - PMC One described flare strategy is a mid- to high-potency topical corticosteroid once daily for 2 to 4 weeks; treatment quantity can be estimated with fingertip units, where 1 fingertip unit is approximately 0.5 g and covers about two adult hand areas, or 2% body surface area. PubMedPubMedAtopic Dermatitis: A Review of Diagnosis and Treatment - PMC Select potency according to lesion thickness, anatomic site, age, and anticipated duration, recognizing that guideline potency recommendations vary. CochraneCochraneStrategies for using topical corticosteroids in children and adults with ...

After control of recurrent disease, use proactive therapy rather than waiting for full relapse. A cited regimen uses low- to medium-potency topical corticosteroid once daily on weekends. PubMedPubMedAtopic Dermatitis: A Review of Diagnosis and Treatment - PMC Guidelines reviewed in a Cochrane analysis generally recommended weekend proactive topical corticosteroid use, although the evidentiary support varied by region and guideline. CochraneCochraneStrategies for using topical corticosteroids in children and adults with ...

Monitor patients requiring prolonged or extensive high-potency topical corticosteroids for local toxicity, including atrophy, striae, rosacea, perioral dermatitis, acne, and purpura. PubMedPubMedAtopic Dermatitis: A Review of Diagnosis and Treatment - PMC Systemic adverse effects are uncommon, but prolonged high-potency exposure can suppress the hypothalamic-pituitary-adrenal axis and produce Cushing syndrome manifestations. PubMedPubMedAtopic Dermatitis: A Review of Diagnosis and Treatment - PMC Recurrent adverse effects or need for continuous high-potency therapy should trigger transition to a steroid-sparing topical agent and consideration of systemic disease control.

For refractory moderate-to-severe atopic dermatitis, systemic options include biologics, oral JAK inhibitors, phototherapy, and conventional immunosuppressive agents. fda+2fda[PDF] NDA Multi-Disciplinary Review and Evaluation: CIBINQO (abrocitinib)nice org uknational institute for health and care excellencePubMedSystemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials - PubMed In a network meta-analysis of 149 randomized trials involving 28,686 patients with moderate-to-severe disease, high-dose upadacitinib was among the most effective therapies for five of six patient-important outcomes; high-dose abrocitinib and low-dose upadacitinib were among the most effective for two outcomes. PubMedPubMedSystemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials - PubMed Oral JAK inhibitors are characterized as highly effective, rapid-onset treatments for moderate-to-severe atopic dermatitis. Oxford AcademicOxford Academicpractical guide to using oral Janus kinase inhibitors for atopic ...

Choose a biologic when a favorable comparative safety profile is prioritized over maximal short-term efficacy. Dupilumab, lebrikizumab, and tralokinumab were of intermediate effectiveness and among the safest systemic options in the network meta-analysis. PubMedPubMedSystemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials - PubMed Dupilumab is FDA approved down to age 6 months; upadacitinib and abrocitinib are approved for patients 12 years and older, while tralokinumab is identified as an IL-13 antagonist option. fda+1fda[PDF] NDA Multi-Disciplinary Review and Evaluation: CIBINQO (abrocitinib)ScienceDirectEmerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients

Abrocitinib is FDA indicated for adults and patients 12 years and older with refractory moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic drug products, including biologics, or when those therapies are inadvisable. fdafda[PDF] NDA Multi-Disciplinary Review and Evaluation: CIBINQO (abrocitinib) When considering an oral JAK inhibitor, explicitly weigh the anticipated benefit of rapid, high-level disease control against class safety considerations and the need for medication-specific prescribing review; do not use systemic corticosteroids as routine long-term management, because they are generally discouraged for safety reasons. ScienceDirect+1ScienceDirectTopical and systemic corticosteroids in the modern Management of Atopic Eczema: A scoping reviewOxford Academicpractical guide to using oral Janus kinase inhibitors for atopic ...

At each reassessment, compare EASI and a patient-reported burden measure with baseline. An EASI reduction of approximately 50% corresponded to one-grade improvement in physician global assessment in a prospective observational study. PubMedPubMedWhat are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study If EASI improves while itch, sleep disturbance, or POEM remains high, investigate ongoing xerosis, excoriation, treatment adverse effects, and diagnostic overlap before labeling the systemic agent ineffective. PubMed+1PubMedRelationship between EASI and SCORAD severity assessments for atopic dermatitisPubMedUpdate on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection

If objective inflammation and patient burden both remain substantial after an adequate topical regimen, move beyond repeated rescue topical corticosteroid cycles. For moderate-to-severe disease, compare systemic options using the patient’s required speed of relief, age eligibility, comparative safety priorities, and feasibility of phototherapy or conventional systemic treatment. fda+4fda[PDF] NDA Multi-Disciplinary Review and Evaluation: CIBINQO (abrocitinib)ScienceDirectEmerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your PatientsOxford Academicpractical guide to using oral Janus kinase inhibitors for atopic ...nice org uknational institute for health and care excellencePubMedSystemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials - PubMed If control is achieved, continue relapse prevention at historically active sites rather than discontinuing all anti-inflammatory topical treatment solely because visible lesions have cleared. PubMed+1PubMedAtopic Dermatitis: A Review of Diagnosis and Treatment - PMCCochraneStrategies for using topical corticosteroids in children and adults with ...